Project description
Precision medicine at the forefront of cancer care
In the EU, cancer has a devastating impact on millions; the staggering mortality rates make it a leading cause of death and morbidity. In this context, the EU-funded PRIME-ROSE project is committed to the Mission Cancer goal. Specifically, it aims to optimise treatments and enhance the quality of life for over 3 million people by 2030. In addition to enhancing access to affordable, life-prolonging treatments, the project will conduct precision cancer medicine trials and bridge gaps in healthcare inequalities. PRIME-ROSE relies on drug rediscovery protocol-like trials, ensuring a bottom-up, clinician-driven approach to bring precision medicine to the forefront of cancer care.
Objective
Millions of people in the EU are negatively affected by cancer, and cancer is one of the leading causes of death and morbidity in Europe (ecis.jrc.europa.eu). The PRIME-ROSE consortium will contribute to the Mission Cancer goal to optimise treatment and support quality of life of more than 3 million people by 2030.
The PRIME-ROSE consortium envisions to support Mission Cancer through the following objectives: 1) increase access to optimised and affordable treatment interventions for cancer patients that prolong life and increase quality of life, 2) generate clinical evidence and evaluate effectiveness in Precision Cancer Medicine (PCM)-relevant and synthetically randomised, controlled academic investigator-initiated pragmatic clinical trials, and 3) work together across Europe with relevant experts to implement evidence-based PCM in routine practice and address inequalities in access.
This consortium builds on the truly bottom-up, clinician-initiated family of DRUP-like innovative trials that provide broad access to precision medicine for cancer patients.
This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.
Fields of science
Programme(s)
- HORIZON.2.1 - Health Main Programme
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
0450 Oslo
Norway
See on map
Participants (8)
2333 ZA Leiden
See on map
113 83 Stockholm
See on map
3400 Hillerod
See on map
00029 Helsinki
See on map
69373 Lyon
See on map
4200-072 Porto
See on map
751 25 Uppsala
See on map
223 61 Lund
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (15)
17177 Stockholm
See on map
291 89 Kristianstad
See on map
69120 Heidelberg
See on map
02-781 Warszawa
See on map
21000 Split
See on map
50406 Tartu
See on map
1122 Budapest
See on map
08035 Barcelona
See on map
6525 GA Nijmegen
See on map
08660 Vilnius
See on map
E20 1JQ LONDON
See on map
M13 9PL Manchester
See on map
D02 CX56 DUBLIN 2
See on map
656 53 Brno
See on map
032266 Bucharest
See on map